In this article, Andrew Butcher writes about the importance of stakeholder engagement as effective but high-cost new therapies have potentially damaging financial implications for the healthcare systems expected to fund them. Regrettably, the pharmaceutical industry is often identified as the cause of the problems rather than the key players in solving them.
IP Insights: Notable developments in IP litigation: April 2021
Sprint Communications Company LP v. WideOpenWest, Inc. et al., Case No. 1-18-cv-00361 (US District Court of Delaware) Sprint Communications filed lawsuits...